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ABSTRACT Molecular dynamics simulations followed by quantum mechanical calculation and Molecular Mechanics Poisson-
Boltzmann Surface Area (MM-PBSA) analysis have been carried out to study binding of proline- and pyrazinone-based
macrocyclic inhibitors (L86 and T76) to human a-thrombin. Detailed binding interaction energies between these inhibitors and
individual protein fragments are calculated using DFT method based on a new quantum mechanical approach for computing
protein-ligand interaction energy. The analysis of detailed interaction energies provides insight on the protein-ligand binding
mechanism. Study shows that T76 and L86 bind to thrombin in a very similar ‘‘inhibition mode’’ except that T76 has relatively
weaker binding interaction with Glu217. The analysis from quantum calculation of binding interaction is consistent with the
MM-PBSA calculation of binding free energy, and the calculated free energies for L86/T76-thrombin binding agree well with the
experimental data.
INTRODUCTION
Human a-thrombin is a multifunctional member of the tryp-
sin family of serine proteases, and it is the ﬁnal enzyme of the
blood coagulation cascade. The activity of thrombin in this
cascade is responsible for the cleavage of ﬁbrinogen to form
ﬁbrin and the activation of platelets via the thrombin receptor
(1–3). Fibrin then polymerizes to form a network of ﬁbers,
entrapping the platelets and leading to clot formation and
cessation of blood ﬂow. Thrombin-induced clot formation is
a necessary part of the wound-healing process, but it is also
associated with many disease states including myocardial
infarction, pulmonary embolism, and stroke (4). While anti-
coagulant therapeutics have traditionally been available in
the form of heparin, which is administered by injection and
the orally active coumadin, both of these treatments have
signiﬁcant limitations in safety and efﬁcacy (5). An inject-
able form of the thrombin inhibitor argatroban has recently
been approved by the FDA, but only for the relatively rare
condition of heparin-induced thrombocytopenia (6). The
direct inhibition of thrombin by an orally available small-
molecule inhibitor is therefore still a high priority in me-
dicinal chemistry research. The inhibition of any of the
closely related serine proteases in the coagulation cascade
might be therapeutically effective, and eventually it may be
possible to selectively inhibit these proteases for optimal
treatment of speciﬁc conditions. Thrombin has also been
implicated in some events at the cellular level such as the
activation of blood platelets and in a number of other pro-
cesses (7). However, at present, the ease with which thrombin
can be puriﬁed and studied in soluble form, along with the
wealth of structural information available and its remarkable
variety of functions in hemostasis (8), has made it the most
intensely studied target for anticoagulation therapy (9–11).
Crystallographic investigations (12) have revealed that
thrombin is composed of disulﬁde-linked A and B chains. It
also has an anion binding exosite positioned;20 A˚ from the
active site along a groove. The active site of thrombin is
mainly deﬁned by the speciﬁcity (S1) pocket, the hydro-
phobic proximal (S2) pocket, and the hydrophobic distal
(S3) pocket. A schematic representation of the active site is
shown in Fig. 1 (13). The speciﬁcity pocket consists of a
hydrophobic channel with the carboxylic acid of Asp189 (14)
and two backbone carbonyls in the bottom of the pocket,
and the former forms strong ionic interactions with amine-,
guanidine-, or amidine-type structures located at the termi-
nus of a hydrophobic spacer. The proximal pocket is deﬁned
on three sides by the Tyr60A and Trp60D side chains of
the 60-insertion loop, the imidazole ring of His57, and the
isobutyl group of Leu99 in the enzyme. The larger distal
pocket is mainly made up of the side chains of Trp215, Ile174,
and Leu99. Other important interactions with potential in-
hibitors include hydrogen bonding to the b-sheet segment
from Ser214-Trp215-Gly216 (15). The catalytic triad of Asp102,
His57, and Ser195 is responsible for the proteolytic activity.
To this end, numerous theoretical studies have been per-
formed to estimate the activities of a series of thrombin
inhibitors. The methods used in these studies include cor-
relation of binding afﬁnity with interaction energy (16),
active site mapping (17), comparative molecular ﬁeld anal-
ysis (18), and linear responses calculations (12). All of these
analyses have their merits as well as weaknesses. A complete
understanding of the binding mechanism of the thrombin
inhibitor complexes is essential for discovery of new and
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improved inhibitors. Due to large size of the enzyme, com-
putational studies of thrombin-inhibitor binding are primar-
ily based on molecular mechanics force-ﬁeld approaches.
Nonetheless, a quantitative analysis of binding interaction
of the thrombin-inhibitor complex at quantum mechanical
level is highly desirable. To aid in the structure-based (or
rational) design of new thrombin inhibitors, we carry out
systematic quantum mechanical studies together with Mo-
lecular Mechanics Poisson-Boltzmann Surface Area (MM-
PBSA) free energy calculations to gain molecular insight
into the binding mechanism of two thrombin inhibitors: the
proline- and pyrazinone-base macrocyclic inhibitors (19–21).
The full quantum mechanical computation of thrombin-in-
hibitor binding interaction energy presented in this study
is made possible by applying a recently developed efﬁcient
molecular fractionation with conjugate caps (MFCC) approach
(22,23). A full quantum study of binding of nevirapine and
efavirenz to HIV-1 RT using the MFCC approach was
recently reported (24,25). In the MFCC approach, the entire
protein is decomposed into amino-acid fragments that are
properly capped and the protein-ligand interaction energy
can be calculated at various levels of quantum mechanical
theory (23). In particular, the method scales linearly, is com-
putationally efﬁcient, and is particularly suitable for com-
putation on multiprocessor computer systems.
THEORY AND METHODS
The MFCC method
The MFCC approach is developed to compute quantum me-
chanical properties of biological molecules such as protein-
ligand interaction (23–27). Below we give a brief description
of the MFCCmethod as applied to the computation of protein-
ligand interaction energy. The main idea of the MFCC
approach is to divide a protein molecule into amino-acid
fragments that are properly capped (23,26). Using the frag-
mentation scheme, the interaction energy between the protein
and another molecule (ligand) can be computed by separate
calculations of individual fragments interacting with the
ligand. A crucial feature of the MFCC approach is that a pair
of conjugate caps (or concaps) is inserted at the location of cut.
These caps are introduced to serve two purposes:
1. They cap the cutoff fragments to satisfy the valency
requirement.
2. They mimic the local chemical environment of the original
protein to the capped fragments.
Fig. 2 illustrates the MFCC scheme in which a peptide bond
is cut and the fragments are capped.
By cutting the peptide bond of the protein into amino-
acid fragments and inserting a pair of concaps, CH3CO-
NHCH3, at the location of cut to cap the fragments, the
interaction energy for protein-ligand binding system (EP-L) is
given by the expression (23–27)
EPL ¼ +
N
i¼1
EFi;L  +
N1
i¼1
ECCiL  +
N
i¼1
EFi 1 +
N1
i¼1
ECCi  +
Nd
i¼1
EDCiL
1 +
Nd
i¼1
EDCi 1 ðNd  1ÞEL; (1)
where EFi;L denotes the ith capped fragment-ligand energy,
ECCiL the ith concap-ligand energy, EFi and ECCi are,
respectively, the self-energy of the capped ith fragment and
ith concap, and EL is the ligand self-energy. For a protein
with N amino acids in a single chain, there are N-1 concaps
needed. EDC-L denotes the disulﬁde concap-ligand energy as
introduced in Chen et al. (27), and Nd is the number of
disulﬁde bonds (27).
In this study, we employ the MFCC method to compute
binding interaction of two thrombin inhibitors (19–21).
The structures of the two inhibitors are shown in Fig. 3,
and we also show the orientations of the two inhibitors in
the active site in the same ﬁgure. Using the MFCC approach,
we ﬁrst decompose the 276 amino acid thrombin into 276
fragments by cutting all the backbone peptide (C-N) bonds,
and there are also 275 concaps formed by the fusion of pairs
FIGURE 1 The schematic representation of the active site of thrombin.
FIGURE 2 The MFCC scheme in which a peptide bond is cut and the
fragments are capped.
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of conjugate caps. In addition, there are four disulﬁde bonds
that are also cut and capped with the SCH3 group (27).
It is worthwhile to mention that the individual fragment-
inhibitor interaction energy from the MFCC calculation is
then decapped to remove the interaction due to the cap
component of the fragment before the interaction spectrum.
Most cap components have negligible interactions with the
inhibitor; only those cap components associated with strong
binding fragments can have appreciable interaction with the
inhibitors. These extra interactions are largely of hydrogen
bonding in nature and are associated with the CO- and NH-
groups in concaps. Although, the MFCC scheme essentially
cancels these ‘‘extra’’ interaction energies to give the correct
total binding energy, it is desirable to remove these extra
energies from the individual fragment energies to show the
interaction spectrum more clearly. The procedure to remove
these cap effects was described in the Appendix of He et al.
(24).
MOLECULAR DYNAMICS SIMULATION
Before the calculations of protein-ligand interaction energy
using MFCC and free energy calculation, a 5-ns molecular
dynamics simulation is performed for these two thrombin-
inhibitor systems to relax the structure and investigate the
dynamics of the binding complex using AMBER8 (28)
para99 (29). Two PDB ﬁles are used as initial thrombin-
inhibitor complex structures for molecular dynamics (MD)
simulation: 1NM6.pdb (19) for THROMBIN-L86 and
1NT1.pdb (19) for THROMBIN-T76. Hydrogen atoms are
added and their positions are optimized. The crystallo-
graphic water molecules in the PDB ﬁles are discarded and
counterions are added to maintain the electroneutrality of the
system. This starting structure was then placed in a truncated
octahedral periodic box of TIP3P water molecules. The
distance between the edges of the water box and the closest
atom of the solutes is at least 8 A˚. The system was minimized
by steepest descent followed by conjugate gradient minimi-
zation. The particle mesh Ewald method (30) is used to treat
long-range electrostatic interactions in a periodic boundary
condition, and bond lengths involving bonds to hydrogen
atoms are constrained using SHAKE (31). The time-step for
all MD simulations is 2 fs, with a direct-space, nonbonded
cutoff of 10 A˚. Applying position restraints with a force
constant to all solute atoms and using the Langevin dynamics
to control the temperature with a collision frequency of 1.0
ps1, 20 ps MD, is carried out at constant volume, during
which the system is heated from 0 to 300 K. Subsequent
isothermal isobaric MD simulation is used for 5 ns to adjust
the solvent density without any restraints on all the solute
atoms. Finally, conformations are collected every 1 ps for
the last 100-ps simulation, and 100 snapshots are collected
for the gas-phase binding energy calculations (32).
We choose the lowest energy structures obtained from
5-ns MD simulation as the binding structure for MFCC cal-
culation of thrombin-inhibitor binding energy. The residues
in 1NM6 and 1NT1 are labeled from 1 to 276, according to
the respective PDB ﬁles. The interaction energies between
inhibitors and missing residues are set to zero. Because the
missing residues in the crystallographic structure are all far
away from the binding site, we just ignored their interactions
with the inhibitors. Considering the computational cost, the
MFCC calculation is performed for all the fragment-inhibitor
interaction pairs at B3LYP/6-31G* level for the thrombin-
inhibitor complex using the Gaussian03 package (33). The
MFCC calculation at B3LYP/6-31G* level generates a
L86-THROMBIN interaction spectrum showing binding
interactions with individual residues as shown in Fig. 4. The
overwhelming majority of enzyme fragments have negligible
interaction with L86, as shown in Fig. 4, and the dominant
binding residues are Ser214, Trp215, Gly216, Asp102. . . in
order of reducing strength.
Table 1 lists the energies of the dominant enzyme fragment-
inhibitor interaction pairs for the two complex structures,
FIGURE 3 Molecular structures of the inhibitors: (a) L86, (b) T76, and
the orientations in the active site of the two inhibitors (c) L86 and (d) T76.
L86 and T76 are displayed in a ball-and-stick representation, and thrombin
is displayed in a surface representation.
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which shows the binding mode of the inhibitors to thrombin
and will be discussed in detail later in the article.
THE MM-PBSA METHOD
Although free energy perturbation and thermodynamic integration calcula-
tions should produce more accurate binding free energies, they are extremely
time-consuming and require sufﬁcient statistical sampling. The heavy
computational cost prevents free energy perturbation and thermodynamic
integration from being routinely used for free energy calculation in structure-
based drug design (34–36). In this work, the binding free energy is
calculated using MM-PBSA (37) and normal mode analysis. We chose 100
snapshots evenly from the last 100 ps MD simulation and calculate the
binding free energies between the two inhibitors and thrombin with MM-
PBSA module in AMBER8. In MM-PBSA, the free energy of A1 B/ AB
is calculated through the thermodynamic cycle36 as shown in Fig. 5. The
absolute binding free energy in condensed phase can be calculated according
to the equation
DGbinding ¼ DGgas  DGAsolv  DGBsolv1DGABsolv
¼ DHgas  TDS DGAPBSA  DGBPBSA1DGABsolv
¼ DHgas  TDS1DDGPB1DDGSA; (2)
where the deﬁnition of various energy terms are clear from Fig. 5. DHgas in
Eq. 2 is the total molecular mechanics energy in the gas phase, and it is
calculated for the unsolvated molecule using the standard AMBER force
ﬁeld with the Sander module of the AMBER program. The electrostatic
contribution to the free energy (DDGPB) is calculated using a ﬁnite dif-
ference solution to the Poisson-Boltzmann (PB) equation, which is solved
by DELPHI program (38). The hydrophobic contribution to the solvation
free energy (DDGSA) is determined from the equation
DGnonpolar ¼ gSA1 b; (3)
where SA is the solvent-accessible surface area that is determined with Paul
Beroza’s Molsurf program, which is based on the analytical ideas primarily
developed by Mike Connolly (39). The values g and b are the empirical
constants used in this work. We also used 0.00542 kcal mol1 A˚2 and 0.92
kcal mol1, respectively, as is standard in the MM-PBSA work that has been
published (40). AMBER99 charge parameters are used again for thrombin
atoms and radius parameters are those taken from the PARSE parameter set
(41). Atomic partial charge parameters for inhibitors are scaled to reproduce
the solvation free energy calculated by PCM method.
Finally, entropy contributions arising form changes in the degrees of
freedom (translational, rotational, and vibrational) of the solute molecules
are included applying classical statistical thermodynamics (32,42). Since the
normal mode calculation of entropy is extremely time-consuming for large
systems, only 20 snapshots (every ﬁfth snapshot of the 100 snapshots) for
each inhibitor are used to estimate the contribution of the entropies to lower
the computational time. Contributions to the vibrational entropy are obtained
by normal-mode analysis. After minimization of each snapshot in the gas-
phase using the conjugated gradient method with a distance-dependent
dielectric of 4r (with r being the distance between two atoms) until the root
mean-square of the elements of the gradient vector is ,104 kcal mol1
A˚1, frequencies of the vibrational modes are computed at 300 K for these
minimized structures using an harmonic approximation of the energies. The
nmode module of the AMBER8 package is used to perform this part of the
calculation (43).
FIGURE 4 MFCC computed interaction energy spectrum (showing inter-
action between the inhibitor and individual protein residues) for L86/thrombin
complex at B3LYP/6-31G* level.
TABLE 1 Interaction energies (kcal/mol) between inhibitors and selected amino-acid fragments of thrombin from ab initio
calculations at B3LYP/6-31G* level
Inhibitor/Residue Asp102 Glu146 Asp189 Ser214 cap214 Trp215 cap215 Gly216 cap216 Glu217
L86 3.9 —z 2.1 6.9 9.7 6.5 (1.8{) 5.8 5.6 6.5 3.0
T76 2.7 2.5 5.7 5.4 7.1 3.6 (3.6{) — 4.7 6.9 —
L86_MP2* 4.8 — 2.7 11.2 NA§ 10.2 NA 14.8 NA 5.6
T76_MP2* 5.7 0.83 8.5 10.8 NA 6.2 NA 10.6 NA —
L86_protonatedy 32.7 — 26.9 10.6 NA 14.5 NA 12.5 NA 39.5
*These values are calculated at MP2/6-311G* level.
yThe interaction energies between protonated L86 and thrombin at B3LYP/6-31G* level.
zThe dash means there is no signiﬁcant interaction between Glu146 and L86, and other dashes in the table also mean there are no strong interactions between
the corresponding inhibitor and residue.
§We do not calculate the interaction between inhibitors and the caps with the level MP2/6-311G*, because of the huge computation cost.
{The value in the parentheses is calculated with small concap CH3-CH3.
FIGURE 5 Thermodynamic cycle for absolute binding free energy
calculation. DGAsolv; DG
B
solv; and DG
AB
solv are solvation free energy of A, B,
and AB, respectively. DGgas and DGbinding are binding free energy in gas
phase and condensed phase, respectively.
Inhibitors of Human a-Thrombin 4247
Biophysical Journal 92(12) 4244–4253
RESULTS AND ANALYSIS
L86 binding to thrombin
L86 and T76 are proline- and pyrazinone-based small
molecules, which inhibit thrombin with a high degree of
potency and selectivity. They are designed by linking the P1
and P3 groups and are synthesized by Merck Research Lab-
oratories (West Point, PA) (19). There are two amines in L86,
and as with many diamines, one of the two amines is usually
protonated in aqueous solution. In this study, however, the
neutral form of the inhibitor is used for the calculation. One
reason is that the active site of thrombin is mostly
hydrophobic, and L86 is inside the cavity free of water.
Another reason is that reliable solvation energy of a charged
ligand is difﬁcult to calculate at present.
Fig. 4 plots the interaction spectrum generated from
the MFCC calculation at B3LYP/6-31G* level for L86/
THROMBIN complex, and it shows that the main binding
attractions come from approximately six residues with
individual gas-phase binding energies .2 kcal/mol. Fig. 6
plots the relative position of L86 in the binding complex with
the residues to which it has strong interactions. As can be
seen from the two ﬁgures, the dominant binding interactions
between the L86 and thrombin are the bindings to Ser214,
Trp215, Gly216, Glu217, Asp102, and Asp189 residue (the num-
bering of the thrombin residues used here is based on the
topological equivalence with chymotrypsin as described by
(14)). The amide NH forms an H-bond with the backbone
carbonyl oxygen of Ser214, and the amide NH from the
pyrazinone and pyrazinone oxygen form two H-bonds with
Gly216.
According to Fig. 6, the distance between the correspond-
ing oxygen atom and nitrogen atom is 3.01 A˚, 3.12 A˚, and
3.15 A˚, and thus these groups have quite favorable geometries
for hydrogen bonding interactions with L86. Fig. 4 shows
strong interaction between the inhibitor and Trp215. Trp215 is
in a very special situation, in that the backbone atoms of Ser214
and Gly216, which are on the sides of Trp215, both form strong
H-bonds with L86; so we checked this energy with the smaller
concap CH3-CH3 instead of the larger cap CH3CO-NHCH3.
In the test calculation, this interaction energy between L86
and Trp215 is substantially reduced, and the data are shown in
the parentheses in Table 1. Thus the strong interaction energy
in the B3LYP/6-31G* level is due to the use of the larger
concap. Because the concap coordinates of Trp215 adopt the
coordinates of the backbone amide nitrogen of Gly216 and the
backbone carbonyl oxygen of Ser214, the calculated binding
interaction of L86 to Trp215 contains the effect of two extra
hydrogen bonds, which are from the concaps and should be
removed.
L86 also has signiﬁcant ion-dipole attractive interactions
with Glu217, Asp189, and Asp102, which is one of the catalytic
triad, as shown in Fig. 6. (L86 is a polar molecule, and its
permanent dipole is;5.6 Debye.) Because the carbon atoms
that interact with Asp102 are directly bonded to chlorine and
nitrogen atoms, there are more positive charges on those
carbon atoms than on the carbon atoms that interact with
Asp189 and Glu217. Thus, the binding to Asp102 is more
favorable than that to Asp189 and Glu217 as shown in Table 1,
which lists the binding energies calculated at the level of
DFT B3LYP/6-31G*. We believe B3LYP/6-31G* is capable
of giving fairly good results on the relative binding energies
of different residues in the gas phase.
The MFCC method is also applied with the protonated
form of L86 for comparison, and we randomly choose an
amine group to add a hydrogen atom. The results are also
shown in Table 1. We only calculate the binding energies of
amino-acid fragments, and the energies between the concaps
and thrombin are not calculated to reduce the computational
cost. As we expected, all the interaction energies are stronger
than the neutral form, especially those amino acids with neg-
ative charges. This is because MFCC calculation only gives
the gas-phase interaction, and the electrostatic interactions
between ions will be overestimated without considering the
solvent effects.
The more reliable results calculated at MP2/6-311G*
levels are shown in Table 1, and we only calculate the inter-
action energies of 12 amino-acid fragments for two inhib-
itors, which have strong interactions at B3LYP/6-31G*
level, due to the heavy computation cost of MP2 calculation.
The basis set superposition error, which results from the use
of an incomplete basis set, is corrected (44). The interaction
energies from MP2/6-311G* calculation are slightly higher
than the results from B3LYP/6-31G*. It is more important,
however, that the relative binding energies of different
residues are essentially similar from different calculations.
The interaction energies calculated at B3LYP/6-31G* level
are in quite good agreement with results computed at the
MP2/6-311G* level expect for Trp215. Here the MP2
FIGURE 6 Relative geometries and distances of L86 and relevant
residues of thrombin in L86/thrombin binding complex.
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calculation also uses the small concap CH3-CH3 for Trp
215.
It is worth noting that the binding interaction at MP2 level is
much stronger than at B3LYP level with the same small
concap. Because other groups found DFT unreliable for
p-stacking, and incapable of including the van der Waals
interaction (45–47), we believe there is also strong hydro-
phobic and aromatic stacking interaction between the phenyl
moiety of the inhibitor and the indole ring of Trp215, and this
kind of interaction with Trp215 also mentioned in Costanzo
et al. (9).
We further investigate the dynamics and ﬂuctuation of the
binding complex in the 5 ns MD simulation in which the
particle mesh Ewald method is carried out in explicit water
for the L86/THROMBIN system. For 100 snapshots
extracted from the last 100 ps of the stable trajectory, gas-
phase binding energies are calculated and averaged using
AMBER force ﬁeld. Fig. 7 shows the comparison between
two force-ﬁeld (from AMBER force-ﬁeld) interaction energy
spectra. The spectrum in Fig. 7 a is calculated using the x-ray
crystallography structure, while the spectrum in Fig. 7 b is
the time-averaged result over the MD collected snapshots.
Here, we found there is no signiﬁcant difference between the
two spectra, and the residues of Asp102, Ser214, Trp215,
Gly216, and Glu217 are still the primary bindings to L86.
Some minor differences between these two spectra can be ob-
served, because MD can relax the experimental structure and
give a more stable conformation comparing with the crystal
structure from the point of view of the complex conformation
as a whole. Thus, the simulation is reasonable and good
enough to obtain lowest energy structure.
Comparing the quantum energy spectrum in Fig. 4 and
those from the force ﬁeld in Fig. 7 for L86-thrombin binding,
it is assuring to see that the dominant interaction proﬁles are
quite similar, with difference only in some details. This is not
surprising since the dominant binding interactions here are
those of hydrogen bonding, which can also be reasonably
represented by the force ﬁeld. Thus, we can also use force-
ﬁeld calculation to provide additional information on the
binding mechanism. Fig. 8 plots the time-dependence of ﬁve
dominant L86-thrombin residue interaction energies calcu-
lated using the AMBER force ﬁeld. Fluctuation in the
interaction energy represents the sensitivity of these values
to conformational details. As shown in Fig. 8, the binding of
L86 to these residues are quite stable.
T76 binding to thrombin
Fig. 9 is similar to Fig. 7 except for T76/thrombin complex,
and it shows the comparison between two force-ﬁeld
interaction energy spectra, one from the x-ray crystal
structure and the other from the time-averaged structure
over the collected MD snapshots. As we can see from the
ﬁgure, the interaction between T76 and Glu146 has changed
from repulsion to attraction after a 5-ns MD run due to the
relaxation, and we obtain more reasonable complex confor-
mation from the MD simulation. Overall, the main interac-
tions between T76 and residues of thrombin are consistent,
so the simulation process is good enough to allow us to ex-
tract structures for MFCC and MM-PBSA calculations.
We follow the same numerical procedure as described
previously to perform MFCC calculation. The computed
interaction spectrum at B3LYP/6-31G* level in Fig. 10
shows that the dominant interactions between T76 and
thrombin are the bindings to Asp189, Ser214, Trp215, Gly216,
Asp102, and Glu146. Fig. 11 plots the relative positions of T76
in complex with these residues having strong binding
interactions.
From the interaction spectrum in Fig. 10 and Table 1, we
notice that T76 and L86 bind to thrombin in a very similar
inhibition mode due to their similar chemical structures. By
FIGURE 7 The interaction spectrum for the L86/
THROMBIN binding complex calculated using the
force ﬁeld from (a) the crystal structure and (b) the
averaged structures over the MD collected snapshots.
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comparing results in Fig. 10 and geometries in Fig. 11, we
can explain the binding character of T76 to thrombin as
follows. Similar to L86, T76 also forms one H-bond to
backbone carbonyl oxygen of Ser214, two H-bonds to Gly216
in an antiparallel b-stand fashion, and ion-dipole attractive
interaction (T76 is also a polar molecule, and its permanent
dipole is;4.0 Debye)withAsp189 andAsp102. In addition, be-
cause Asp189 interact with the carbon atoms that are directly
bonded to chlorine and oxygen atoms with the distance of
5.13 A˚, 5.71 A˚, and 6.56 A˚, the binding energy between
Asp189 and T76 is signiﬁcantly larger than that between
Asp189 and L86.
We also calculated individual thrombin fragments-T76
interaction energies for several dominant binding residues at
MP2/6-311G* level as shown in Table 1. As we can see
clearly from the table, most of the calculated interaction
energies using both MP2/6-311G* and B3LYP/6-31G*
method are in close agreement with each other, with the
MP2/6-311G* energies being slightly higher in general.
Similarly, we believe there is also signiﬁcant interaction be-
tween T76 and Trp215, as in the case for L86 according to the
MP2 result.
The interaction between Glu146 and T76 at different
computational levels is a little different. The MP2 result
shows there should be weak repulsion between them, while
their interaction should be attractive interaction at the
B3LYP level. We also check the structure from the MD sim-
ulation, and there is no bridge water between them to form
extra H-bonds to reduce the repulsion. Although the results
at different levels are not exactly consistent, the strong
repulsion between them in the crystal structure is highly
reduced after MD simulation. Examination of the relative
geometry in Fig. 11 shows that the distance is 6.15 A˚
FIGURE 9 Similar to Fig. 7 except for the T76/
thrombin complex.
FIGURE 8 The time-dependence of interaction energies calculated us-
ing AMBER force ﬁeld for the ﬁve dominant residues binding to L86 for
100 consecutive snapshots of the L86/thrombin complex.
FIGURE 10 MFCC computed interaction energy spectrum for T76/
THROMBIN complex at B3LYP/6-31G* level.
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between the oxygen atom of T76 and the negatively charged
carboxyl group of Glu146, and this may be the source of the
weak repulsion.
DISCUSSION AND CONCLUSION
The MFCC method has been applied to study binding
mechanism of L86 and T76 to human a-thrombin at DFT
level. In addition, molecular dynamics simulation has been
carried out to investigate the dynamics and stability of the
thrombin-inhibitor complex and to calculate binding free
energy using the MM-PBSA approach. Our study shows that
the strong bindings of L86 to Ser214, Gly216, Trp215, Glu217,
Asp102, and Asp189 are the primary mechanism of drug binding
to thrombin, and T76 binds to thrombin in a very similar in-
hibition mode to L86, except that T76 has a relatively weaker
interaction with Glu217 in the quantum calculation.
The overall gas-phase interaction energies of the two
inhibitors from MFCC are almost the same to each other
(;33.9 kcal/mol), and this is likely due to the similar
binding mode of the two inhibitors. Calculated free energies
of binding from MM-PBSA are listed in Table 2, and they
are 14.6 and 13.3 kcal/mol, respectively, for bindings of
L86 and T76 to thrombin. Although the current MFCC
calculation does not attempt to provide a quantitative
comparison between theoretical calculation and the observed
experimental binding afﬁnities, both the MM-PBSA and
MFCC calculations draw the same conclusion that binding
energies of L86/thrombin and T76/thrombin are close to
each other because of similar binding modes. Thus, MFCC
calculation is consistent with the result from MM-PBSA
calculation, though MFCC only gives the gas-phase inter-
action energy. The free energies for L86/T76-thrombin
binding from MM-PBSA calculation are consistent with the
experiment values of Nantermet et al. (19).
Current computational study provides an easy means to
extract molecular insight of protein-ligand binding by explic-
itly calculating the interaction energy between individual
residues and the ligand at quantum mechanical levels. These
individual residue-ligand interaction energies provide detailed
quantitative information about speciﬁc residue interaction
with the ligand that should be extremely useful for our
understanding of the molecular nature of protein-ligand
binding. This gas-phase binding energy analysis is comple-
mentary to MD simulation and free energy calculation, and
therefore provides additional insight into the mechanism of
protein-ligand binding at quantum mechanical levels.
Some words on the level of quantum chemistry calculation
are warranted here. Because current DFT or Hartree-Fock
calculations are incapable of giving van der Waals (or
dispersion) energies, it is desirable to employ higher level of
quantum chemistrymethods to perform such calculation. This
is possible and practical with the MFCC approach, as was
demonstrated in a recent study of water-protein interaction at
the MP2 level (48). Future studies will be carried out to
investigate the dispersion interaction energies using higher-
level quantum chemistry methods or mixed methods with
higher-level theory for close contact residues andHF/DFT for
more distant residues. Of course, signiﬁcantly higher com-
putational cost will be needed when higher-level quantum
methods with larger basis sizes are employed.
Another issue to be investigated in the future is the solvent
effect. How these individual amino acid-ligand interactions
energies are affected by the presence of solvent is also very
important. A new method (49) is being developed by this
group to include the solvent effect in the MFCC study of
proteins and such applications are currently being planned.
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TABLE 2 Binding free energies (kcal/mol) from MM-PBSA
calculation and normal mode analysis for two
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Inhibitors L86 T76
DHBbB(s) 37.7 34.8
D(TS)BbB(s) 23.1 21.5
DGBbB(s) 14.6 13.3
DGBbB(experiment)* 13.7* 12.2*
*The experimental binding free energies (13.7 and 12.2) are calculated
using Ki, which are provided in Nantermet et al. (19).
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